Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report
Endometrial cancer remains the most common gynecologic malignancy in the United States. Novel molecular targets are being explored for treatment of advanced uterine. Molecular targets in signaling cascades have been identified including immune checkpoint inhibitors. This is a case of 63-year-old G0...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Elsevier
2024-06-01
|
| Edice: | Current Problems in Cancer: Case Reports |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2666621924000085 |